These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Safety of long-acting beta-agonists--an urgent need to clear the air. Martinez FD N Engl J Med; 2005 Dec; 353(25):2637-9. PubMed ID: 16371628 [No Abstract] [Full Text] [Related]
4. Cause of death in the SMART Trial. Williams C Chest; 2006 Sep; 130(3):929-30; author reply 930. PubMed ID: 16963700 [No Abstract] [Full Text] [Related]
13. Long acting beta 2 agonists and the risk of life threatening asthma. Ernst P Thorax; 1998 Jan; 53(1):1-2. PubMed ID: 9577513 [No Abstract] [Full Text] [Related]
14. [More asthma death cases with beta-2-antagonists: with inhaled corticosteroids on the safe side?]. Wepner U MMW Fortschr Med; 2007 Dec; 149(49-50):20. PubMed ID: 18240436 [No Abstract] [Full Text] [Related]
15. Salmeterol xinafoate: an analysis of outcomes and cost-effectiveness using a primary care database. Price DB; Cargill K; Wolfe S; Darby H Respir Med; 1998 Nov; 92(11):1302-4. PubMed ID: 9926144 [No Abstract] [Full Text] [Related]
16. Exacerbations of asthma in patients on salmeterol. Jenkins MM; Hilton CJ; de Kock JC; Palmer JB Lancet; 1991 Apr; 337(8746):913-4. PubMed ID: 1672988 [No Abstract] [Full Text] [Related]
20. The US Food and Drug Administration and long-acting beta2-agonists: the importance of striking the right balance between risks and benefits of therapy? Lemanske RF; Busse WW J Allergy Clin Immunol; 2010 Sep; 126(3):449-52. PubMed ID: 20692690 [No Abstract] [Full Text] [Related] [Next] [New Search]